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Abstract
Objectives—To examine time intervals from cervical cancer screening to diagnosis and 
treatment initiation among low-income and uninsured women in the National Breast and Cervical 
Cancer Early Detection Program (NBCCEDP) during two consecutive time periods.
Methods—We analyzed NBCCEDP data for women with abnormal Pap tests (n = 100,167), 
from which 1,417 invasive cervical cancers were diagnosed. We examined two time intervals for 
this study: diagnostic interval (time from abnormal Pap test to the date of definitive diagnosis) and 
treatment initiation interval (time from definitive diagnosis to treatment initiation) for two time 
periods: 1996–2002 and 2003–2009. We compared median time intervals for diagnostic and 
treatment initiation using the Kruskal-Wallis test. Adjusted proportions (predicted marginals) were 
calculated using logistic regression to examine diagnosis and treatment within program 
benchmarks (≤ 60 days).
Results—Median diagnostic intervals decreased overall by 6 days (54 vs. 48 days, p < 0.001). 
This decrease in the median diagnostic interval was noted for all variables examined. The median 
treatment initiation intervals remained stable over the two time periods.
Conclusions—Women screened by the NBCCEDP receive diagnostic follow-up and initiate 
treatment within preestablished program guidelines.
Introduction
For cancer screening to be beneficial, it is imperative that patients receive timely and 
appropriate follow-up for screening-detected abnormalities as a prerequisite to appropriate 
treatment. Failure to obtain appropriate diagnostic services can have a significant negative 
effect on health outcomes, as well as costs for both the individual and the healthcare 
system.1 A systematic review of follow-up care after abnormal screening tests for cervical, 
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breast, and colon cancer showed that < 75% of women received timely and appropriate 
follow-up care.2 The proportion of women who were followed after abnormal Pap tests 
varies dramatically across studies, ranging from 7% to 73%.2,3
Cervical cancer is preventable through early detection and removal of premalignant changes. 
There are few data to indicate what the optimal diagnostic and treatment intervals are that 
might ensure the best chances of survival from cervical cancer detected by screening. 
However, studies have shown that a longer time to treatment, specifically in the medically 
underserved, results in later stage disease and, thus, poorer survival.4 Minority and 
uninsured women and women from lower socioeconomic backgrounds are less likely to 
participate in screening,5 less likely to have timely and complete follow-up after an 
abnormal test result,6 and more likely to be diagnosed with late-stage disease.7
The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) was 
authorized by Congress in 1990 to reach underserved women.8 Since the inception of the 
program, the NBCCEDP established quality standards to assure timely and complete 
diagnostic follow-up and treatment initiation for underserved women screened through the 
program. Legislation for program enhancements that added case management services in 
2000 and a Medicaid waiver to support cancer treatment authorized by Congress and 
implemented in 2003 were expected to improve the ability of programs to meet these 
standards.9,10 Revisions were also made in the reporting system of Pap test results 
(published in 2002) to more clearly identify cell changes,11 along with the introduction of 
the first evidence-based guidelines for management of abnormal Pap tests (published in 
2002).12,13 With these improvements both programmatically and reporting, we hypothesized 
that NBCCEDP quality measures would improve over time (i.e., shortening of time 
intervals) and that more women would meet the program standards. We used two equal 7-
year periods, 1996–2002 and 2003–2009, to determine if the intervals have decreased and 
the percent meeting program standards has improved with implementation of program 
enhancements and changes within the cytologic management of reporting and guidelines, 
which would all have been in place by the second time period.
Materials and Methods
The Centers for Disease Control and Prevention (CDC) implemented cooperative 
agreements with states, American Indian/Alaska Native tribes, and territories to provide 
screening, referral, and follow-up services to women through the NBCCEDP, which has 
been described in detail elsewhere.8
Since the program’s inception in 1991, the CDC has used a set of standardized data items to 
monitor screening, diagnostic follow-up, and treatment initiation activities. Women reported 
demographic characteristics and prior screening history at enrollment. Providers reported 
dates and results of Pap tests as well as any diagnostic procedures, outcomes, and the date of 
treatment initiation if applicable. For this study, data from 50 states, the District of 
Columbia, 13 tribes, and 4 territories were used for the study period 1996–2009. Each 
woman’s county of residence and a U.S. Census data file were used to categorize residence 
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at the time of screening as metropolitan, urban, or rural based on the Rural/Urban 
Continuum Code.14 This study was approved by the CDC’s Human Subjects Committee.
Study outcomes
We considered two time intervals for this study: diagnostic interval (time from the first 
abnormal Pap test to the date of definitive diagnosis, which is specified as the date of the 
procedure that confirmed a diagnosis) and treatment initiation interval (time from definitive 
diagnosis to treatment initiation). The diagnostic interval examined the abnormal screening 
test results defined by the Bethesda reporting system11 as low-grade squamous 
intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), and 
squamous cancer (SqCa). Treatment intervals examined invasive cervical cancers only. 
Outcomes were examined for two 7-year time periods. Time 1 encompassed 1996–2002, 
and time 2 encompassed 2003–2009.
Study population
During the study period from January 1, 1996, through December 31, 2009, 4,402,242 Pap 
tests were provided to 2,486,028 women aged ≥ 18 years (Fig. 1). Among the 2,486,028 
women screened, 121,476 women were found to have an abnormal Pap test. A total of 
21,309 women were excluded because of missing or invalid service dates or lost to follow-
up or refusal of diagnostic workup or treatment. The final study population consisted of 
100,167 women with abnormal screening test results and 1,417 invasive cervical cancers. 
Time 1 included 33,917 women with abnormal screening test results and 543 cancers, and 
time 2 included 66,250 women with abnormal screening test results and 874 cancers.
Data analysis
The distributions of characteristics of the women with abnormal Pap tests, including Pap test 
result, age, race/ethnicity, and residence, were provided by time period. Chi-square tests 
with p values were performed to test for association between the characteristics by time 
period. The diagnostic and treatment interval distributions were highly skewed because of a 
few outliers. Therefore, we compared medians rather than means to provide a more accurate 
picture of the true distributions, using the Kruskal-Wallis test to assess statistical 
significance. We calculated median days and interquartile ranges (IQRs). We created 
multivariate logistic models stratified by time period, as significant interactions were found 
between time periods and all covariates included in the final model. We used logistic 
regression analysis to produce adjusted proportions (predicted marginals, [PM]) to examine 
diagnosis and treatment within program standards (≤ 60 days), controlling for screening test 
results, age, race/ethnicity, and residence. In our logistic regression model, timeliness was 
the dependent variable, and screening test results, age, race/ethnicity, and residence were 
independent variables. Additionally, the percentages of women meeting the program 
standards for all years (1996–2009) for diagnosis and treatment were shown and tested for 
time trends. All statistics were generated using SUDAAN version 9.0 (Research Triangle 
Institute, Research Triangle Park, NC) and SAS version 9.1 (SAS Institute Inc., Cary, NC).
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Most women in the study had a less severe abnormal Pap result (LSIL), were < 40 years old, 
were white, and lived in a metropolitan area (Table 1). Pap tests reported as LSIL increased 
from 65% in time 1 to 73% in time 2.
Table 2 displays median diagnostic intervals with IQRs and the adjusted proportions for 
women with an abnormal Pap test being diagnosed within the program standard of 60 days. 
For the diagnostic interval, the overall median time to diagnosis decreased from 54 to 48 
days over the two time periods ( p < 0.001). The biggest improvements in the median 
diagnostic interval occurred among women who had a Pap test result of SqCa (33 vs. 22 
days, time 1 to time 2, p < 0.001), 18–29-year-olds (61 vs. 50 days, time 1 to time 2, p < 
0.001), and black women (61 vs. 50 days, time 1 to time 2; p < 0.001). With the exception of 
Asian women, racial and ethnic minorities had longer median times to diagnosis and 
treatment compared to whites (by 5–10 days in time 1 and 3 days in time 2). Women 
residing in rural areas had a shorter median diagnostic interval compared to metropolitan 
and urban areas for both time periods. Women with a diagnosis of cancer had a significantly 
shorter time than those without cancer for both time periods.
Table 2 also presents adjusted proportions (PM) and 95% confidence intervals (CI) for 
women being diagnosed within the program standard of 60 days. Stratified models were 
constructed to examine the differences within each time period. For the diagnostic interval, 
all subgroups improved in meeting the 60-day standard. Women with SqCa had the largest 
improvement in diagnostic interval from time 1 to time 2 of meeting the 60-day program 
benchmark, from 73% (95% CI 69%–76%) to 88% (95% CI 85%–90%), respectively.
Table 3 displays the treatment initiation intervals with IQRs and the adjusted proportions 
(PM) for women initiating treatment within the program standard of 60 days. For the 
treatment interval, the overall median time from diagnosis to treatment initiation decreased 
from 22 to 21 days over the two time periods. The median times improved over time for 
most subgroups of women; however, there were no statistically significant differences in 
median days among the variables noted. For the PM, the only statistically significant 
covariate was Pap test screening result (for time 2).
Figure 2 represents the changes in diagnostic and treatment intervals from 1996 to 2009. 
Women receiving a diagnosis within 60 days of an abnormal screening test result (program 
standard) improved from 56% in 1996 to 71% in 2009 ( p < 0.001). The first significant 
increase in the percentage meeting standards occurred in 2003 with 60%. The treatment 
intervals fluctuated across time period.
Discussion
Overall, 69% of women with an abnormal Pap test in the NBCCEDP were diagnosed within 
60 days after a high-grade diagnosis (68% HSIL and 83% SqCa), and 88% initiated 
treatment within 60 days after a high-grade diagnosis (86% HSIL and 91% SqCa) (data not 
shown). The median intervals measured decreased over the two time periods, diagnosis by 6 
days and treatment by 1 day. Women with higher-grade lesions were diagnosed in shorter 
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time periods, and this improved over time, with a median of only 22 days in time 2. The 
NBCCEDP specifies that follow-up systems with appropriate diagnostic and treatment 
reminders be in place to track and monitor care before implementing screening to ensure 
that programs meet standards for timeliness and are able to provide feedback to providers.15 
We found that the proportion of women meeting program standards increased for diagnosis. 
Most of the improvements occurred in the second time period, when case management and 
state’s Medicaid waivers were fully implemented9,10 and improvements in the detection, 
reporting, and management of cervical cancer were made (published in 2002 and required in 
NBCCEDP data collection in 2003).11,12
Although program standards for timeliness have been met for the majority of women since 
1996 (Fig. 2), differences in diagnostic intervals are noted for all subpopulations studied 
(Table 2). The greatest variations have been observed among racial and ethnic minorities. 
Median diagnostic intervals for minority women are longer in both time periods, with the 
exception of Asian women whose intervals are similar to those of white women. However, 
black and Hispanic women’s proportions in meeting the standard have increased more than 
white women’s, so the gap has closed considerably (Hispanic from 7% to 4% fewer than 
white, black from 11% to 6%).
This finding regarding women of racial or ethnic minorities with longer waiting times for 
diagnosis after cervical cancer screening was also noted in a study of underserved women in 
California.6 Additionally, Richardson et al.16 examined the timeliness of breast cancer 
diagnosis and treatment in the NBCCEDP and also found that minority women had longer 
median times to diagnosis of breast cancer than did white women. There may be multiple 
explanations for these findings, including individual characteristics, miscommunication of 
results, provider characteristics, or the healthcare facilities where minorities receive 
care.17,18 More research is needed within this program to address the racial and ethnic 
differences observed among a similar underserved population. Although these differences 
are not clinically significant, women are under psychologic stress waiting for abnormal 
results to be resolved.19
The standards of 60 days for diagnosis and treatment were established at the initiation of the 
program based on best clinical judgment at the time. To date, there are no scientific data that 
suggest the 60-day interval for a timely diagnosis is insufficient. Data suggest that the 
sooner a diagnosis is made and the condition treated, the better the outcome.4 Several 
programs, however, have been challenged to meet the 60-day diagnosis interval performance 
measure that requires at least 75% of abnormal screening tests be resolved. Typical 
challenges encountered by programs include waiting lists for colposcopy appointments, 
rescheduled appointments, and difficulty referring women.20 With the lack of scientific data 
in the literature and extended conversations with experts in the field, CDC changed the 
performance measure in November 2009 to 90 days.21 Looking at the most recent time 
period (2003–2009), > 80% of the programs were meeting the new 90-day requirement.
Over the time period of the study, many advances in the prevention and detection of cervical 
cancer have occurred. These advances reflect a greater understanding of the natural history 
of the human papillomavirus (HPV) infection and its role in the development of cervical 
Benard et al. Page 5













cancer.11,12,22 Younger women are more likely to have a high clearance of HPV infections 
and regression of Pap abnormalities to normal and, therefore, could have a more 
conservative follow-up approach, as suggested by updated management guidelines.13 Our 
data clearly show that the youngest group (aged 18–29) has a longer time to diagnosis 
compared to the other age groups and that the median number of days decreases with 
increasing age (Table 2), suggesting that providers understand this relationship. The median 
days for treatment for the younger age group are comparable to other ages, however, 
suggesting that if the lesion is advanced to cancer, they are obtaining timely treatment.23
Also in the advances in cervical cancer early detection, the reporting system improved11 
(published in 2002), and evidence-based management guidelines12 (published in 2002) were 
adopted. The new Bethesda terminology divided the equivocal cytology category to include 
a high-grade component. Because this category did not exist in the earlier time period, we 
opted not to include this category in our abnormal results. Additionally, the management 
guidelines changed, now recommending an immediate colposcopy for an LSIL Pap test 
result.12 Before the published guidelines in 2002, the recommended follow-up for LSIL was 
a repeat Pap test at 4–6 months for 2 years.24 This change in reporting and management 
guidelines could be why we see an increase in the percent of LSIL Pap results in the second 
time period. Also of note is the increase in the number of abnormal Pap tests overall from 
time 1 to time 2 (33,917 and 66,250, respectively) The NBCCEDP began in 1991 with very 
few states and each year grew in number and funding; this stabilized in 2007. There were a 
total of 1,117,605 women screened in time 1 and 1,368,423 in time 2.
In an insured population, investigators found the median length of time from an abnormal 
Pap test to the recommended colposcopy was 99 days25; this was much longer than the 50 
days (overall time period) that we observed in the NBCCEDP underserved population 
without insurance. In an organized screening program in New Zealand, 9% of women 
experienced a delay (defined as > 6 months or 180 days) from high-grade cytology result to 
diagnosis.26 We report a 5% overall delay over 180 days to diagnosis; this includes low-
grade abnormalities, which generally result in longer times overall (data not shown).
Limitations and strengths
Our study has several limitations. The program collects only minimal data elements, such as 
the demographics of the patients; however, we lack information about some patient 
characteristics that may influence a provider’s follow-up and management plan. We are also 
not able to track the receipt of services outside the program. If a woman received follow-up 
outside the program, we would not be able to capture this information, and our results could 
underestimate true follow-up. Additionally, there was a large percentage (17.5% overall) of 
women excluded from the cohort because of missing values, lost to follow-up, or refused. 
Table 1 provides the characteristics of these women; those who were excluded had more 
LSIL Pap test results, were older ( > 40 years old), and were not white, compared to the 
cohort studied (for time 1 and time 2). The percentage of women excluded from the study 
decreased with time (19.4% time 1 vs. 16.5% time 2). Our results may not be generalizable 
to the women not served by the program. However, Saraiya et al.27 found that in a national 
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survey of primary care providers, the NBCCEDP providers were similar to the population in 
their cervical cancer screening beliefs and practices.
The NBCCEDP is the only national screening program for cervical cancer in the United 
States. More than 2.6 million women have been screened for cervical cancer since 1991, 
with a focus on underserved women of racial and ethnic minorities. Although information 
on behavioral risk factors is lacking, more than 20 years worth of data are available to assess 
follow-up patterns over time. Moreover, this large collection of clinical data enables a 
window into the practices of thousands of providers across the United States, operating in a 
multitude of clinical settings.
Conclusions
The goal to expand health insurance coverage in the United States has placed new emphasis 
on the effectiveness of existing public health programs. However, improved access to health 
services alone does not guarantee effective cancer control and prevention. Even with a 
national program to help reduce the barriers to early detection, our results still show 
disparities across racial and ethnic groups. Overall, the program has continued to improve 
within each subpopulation over time. Results from our study indicate that underserved 
women screened by the NBCCEDP do receive timely diagnostic follow-up and treatment 
initiation, as measured by program standards. National standards for all cervical cancer 
screening programs or similar healthcare delivery systems could be modeled on the program 
standards to ensure that all women receive adequate follow-up care.
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Study population in the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP), 1996–2009. *Abnormal Pap tests include low-grade squamous intraepithelial 
lesion, high-grade squamous intraepithelial lesson, and squamous cancer.
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Percentage meeting the 60-day diagnostic and treatment intervals in the NBCCEDP, by year
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